Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 4, 2014, Pages 970-976

  Shimizu, Koichi ^a   Kotera, Yoshihito ^a   Aruga, Atsushi ^a   Takeshita, Nobuhiro ^a   Katagiri, Satoshi ^a   Ariizumi, Shun Ichi ^a   Takahashi, Yutaka ^a   Yoshitoshi, Kenji ^a   Takasaki, Ken ^a   Yamamoto, Masakazu ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; Adoptive transfer; Cancer vaccine; Dendritic cell; Hepatocellular carcinoma; Immunotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DENDRITIC CELL VACCINE; CANCER VACCINE;

ADOPTIVE TRANSFER; ADULT; ARTICLE; BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL TRANSFER; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; SKIN REDNESS; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; AGED; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL (TOPIC); DENDRITIC CELL; IMMUNOLOGY; LIVER NEOPLASMS; POSTOPERATIVE CARE; PROCEDURES; RECURRENT DISEASE; T LYMPHOCYTE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOPTIVE TRANSFER; ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELLS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-RANDOMIZED CONTROLLED TRIALS AS TOPIC; POSTOPERATIVE CARE; RECURRENCE; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899798695     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27678     Document Type: Article

References (28)

1. ImamuraH, MatsuyamaY, TanakaE, OhkuboT, HasegawaK, MiyagawaS, SugawaraY, MinagawaM, TakayamaT, KawasakiS, et al.Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol2003; 38:200-7; PMID:12547409; http://dx.doi.org/10.1016/ S0168-8278(02)00360-4
2. TakayamaT, SekineT, MakuuchiM, YamasakiS, KosugeT, YamamotoJ, ShimadaK, SakamotoM, HirohashiS, OhashiY, et al.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.Lancet2000; 356:802-7; PMID:11022927; http://dx.doi.org/10.1016/S0140- 6736(00)02654-4
3. Engell-NoerregaardL, HansenTH, AndersenMH, Thor StratenP, SvaneIM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer ImmunolImmunother2009; 58:1-14; PMID:18719915; http://dx.doi.org/10.1007/s00262-008-0568-4
4. ShimizuK, KoteraY, ArugaA, TakeshitaN, TakasakiK, YamamotoM. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma.J HepatobiliaryPancreatSci2012; 19:171-8; PMID:21874278; http://dx.doi.org/10. 1007/s00534-011-0437-y
5. LiuS, ZhangH, GuC, YinJ, HeY, XieJ, CaoG. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst2009; 101:1066-82; PMID:19574418; http://dx.doi.org/10.1093/ jnci/djp180
6. AltekruseSF, McGlynnKA, ReichmanME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J ClinOncol2009; 27:1485-91; PMID:19224838; http://dx.doi.org/10.1200/JCO.2008.20. 7753
7. LlovetJM, RicciS, MazzaferroV, HilgardP, GaneE, BlancJF, de OliveiraAC, SantoroA, RaoulJL, FornerA, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857
8. ZhangCH, XuGL, JiaWD, GeYS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer2009; 124:2982-8; PMID:19296539; http://dx.doi.org/10.1002/ijc.24311
9. YoshidaH, ShiratoriY, KudoM, ShiinaS, MizutaT, KojiroM, YamamotoK, KoikeY, SaitoK, KoyanagiN, et al.Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.Hepatology2011; 54:532-40; PMID:21574174; http://dx.doi.org/10.1002/hep.24430
10. ChenT-T. Statistical issues and challenges in immuno-oncology.J Immunother Cancer2013; 1:18; http://dx.doi.org/10.1186/2051-1426-1-18
11. OgiC, ArugaA. Clinical evaluation of therapeutic cancer vaccines.Hum VaccinImmunother2013; 9:1049-57; PMID:23454867; http://dx.doi.org/10.4161/hv. 23917
12. CheeverMA, HiganoCS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.Clin Cancer Res2011; 17:3520-6; PMID:21471425; http://dx.doi.org/10.1158/1078-0432.CCR-10-3126
13. ArugaA, TakeshitaN, KoteraY, OkuyamaR, MatsushitaN, OhtaT, TakedaK, YamamotoM. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer.Clin Cancer Res2013; 19:2224-31; PMID:23479678; http://dx.doi.org/10.1158/1078-0432.CCR-12-3592
14. MatsushitaN, ArugaA, InoueY, KoteraY, TakedaK, YamamotoM. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Oncol Rep2013; 29:951-9; PMID:23314271
15. KonoK, IinumaH, AkutsuY, TanakaH, HayashiN, UchikadoY, NoguchiT, FujiiH, OkinakaK, FukushimaR, et al.Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.J Transl Med2012; 10:141; PMID:22776426; http://dx.doi.org/10.1186/1479-5876-10-141
16. ChenIP, AriizumiS, NakanoM, YamamotoM. Positive glypican-3 expression inearly hepatocellular carcinoma predicts recurrence after hepatectomy.J Gastroenterol2013; (Forthcoming);;http://dx.doi.org/10.1007/s00535-013-0793-2
17. SawadaY, YoshikawaT, NobuokaD, ShirakawaH, KuronumaT, MotomuraY, MizunoS, IshiiH, NakachiK, KonishiM, et al.Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.Clin Cancer Res2012; 18:3686-96; PMID:22577059; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044
18. KoikeN, Pilon-ThomasS, MuléJJ. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.J Immunother2008; 31:402-12; PMID:18391755; http://dx.doi.org/10.1097/CJI.0b013e31816cabbb
19. MatsushitaN, Pilon-ThomasSA, MartinLM, RikerAI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model.J Immunol Methods2008; 333:167-79; PMID:18295790; http://dx.doi.org/10.1016/j.jim.2008.01. 012
20. MorseMA, HobeikaAC, OsadaT, SerraD, NiedzwieckiD, LyerlyHK, ClayTM. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood2008; 112:610-8; PMID:18519811; http://dx.doi.org/10.1182/blood-2008-01-135319
21. HamidO, RobertC, DaudA, HodiFS, HwuWJ, KeffordR, WolchokJD, HerseyP, JosephRW, WeberJS, et al.Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.N Engl J Med2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
22. BrahmerJR, TykodiSS, ChowLQM, HwuWJ, TopalianSL, HwuP, DrakeCG, CamachoLH, KauhJ, OdunsiK, et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
23. WolchokJD, KlugerH, CallahanMK, PostowMA, RizviNA, LesokhinAM, SegalNH, AriyanCE, GordonRA, ReedK, et al.Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/ NEJMoa1302369
24. OgiC, ArugaA. Immunological monitoring of anticancer vaccines in clinical trials.Oncoimmunology2013; 2:e26012; PMID:24083085; http://dx.doi.org/10.4161/ onci.26012
25. ElliottRL, HeadJF. Adjuvant breast cancer vaccine improves disease specific survival of breast cancer patients with depressed lymphocyte immunity. SurgOncol2013; 22:172-7; PMID:23791552; http://dx.doi.org/10.1016/j.suronc.2013. 05.003
26. ChangAE, ArugaA, CameronMJ, SondakVK, NormolleDP, FoxBA, ShuS. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.J ClinOncol1997; 15:796-807; PMID:9053507
27. KandalaftLE, PowellDJJr., ChiangCL, TanyiJ, KimS, BoschM, MontoneK, MickR, LevineBL, TrigianDA, et al.Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccin-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunlogy2013; 2:1-9
28. GalonJ, PagèsF, MarincolaFM, ThurinM, TrinchieriG, FoxBA, GajewskiTF, AsciertoPA. The immune score as a new possible approach for the classification of cancer.J Transl Med2012; 10:1; PMID:22214470; http://dx.doi.org/10.1186/1479-5876-10-1